Skip to main content
Fig. 4 | Translational Neurodegeneration

Fig. 4

From: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

Fig. 4

Correlation of CMA with plasma metabolites and altered plasma protein levels. a Associations between the plasma levels of individual CMA and the 10 most significantly correlated plasma metabolites. Asterisks indicate statistical significance (Adjusted P < 0.05) based on Spearman correlation analysis. Cor.Coeff: Correlation coefficient. b Heatmap showing log2FC-based significantly different proteins on day 84 vs day 0 in the CMA and placebo groups. Asterisks indicate statistical significance based on paired Student’s t-test (P < 0.01). c Integrated multi-omics data based on network analysis represent the neighbours of the CMA, including serine, carnitine, nicotinamide and cysteine, and ADAS-Cog scores. Only analytes that were significantly altered in CMA on day 84 vs day 0 are highlighted

Back to article page

Translational Neurodegeneration

ISSN: 2047-9158

Contact us